癌症免疫治疗学会（SITC）关于免疫疗法治疗急性白血病的临床实践指南。
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.
机构信息
Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Virginia Cancer Specialists, Fairfax, Virginia, USA.
出版信息
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-000810.
Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.
急性白血病是一组快速进展的疾病，影响范围广泛，无论患者的年龄或性别如何。急性白血病患者的传统治疗选择包括化疗和造血细胞移植。癌症免疫疗法的出现对急性白血病的治疗产生了重大影响。新型免疫治疗药物包括抗体药物偶联物、双特异性 T 细胞衔接器和嵌合抗原受体 T 细胞疗法，具有疗效，并已被美国食品和药物管理局 (FDA) 最近批准用于治疗急性白血病患者。癌症免疫治疗学会 (SITC) 召集了一组专家，制定了一份临床实践指南，其中包含关于免疫疗法治疗急性淋巴细胞白血病和急性髓细胞白血病的共识建议。
Zotero 插件